REYON Pharmaceutical Co., Ltd. (102460.KS)
KRW 13020.0
(-2.18%)
KRW 13020.0
(-2.18%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 121 Billion KRW | -34.75% |
| 2022 | 185.44 Billion KRW | 1.39% |
| 2021 | 182.9 Billion KRW | 401.87% |
| 2020 | 36.44 Billion KRW | 90.25% |
| 2019 | 19.15 Billion KRW | -45.69% |
| 2018 | 35.26 Billion KRW | 3.61% |
| 2017 | 34.03 Billion KRW | 0.0% |
| 2016 | - KRW | 0.0% |
| 2015 | - KRW | 0.0% |
| 2014 | - KRW | 0.0% |
| 2013 | - KRW | 0.0% |
| 2012 | - KRW | 0.0% |
| 2011 | - KRW | -100.0% |
| 2010 | 408.95 Million KRW | -63.15% |
| 2009 | 1.1 Billion KRW | -36.0% |
| 2008 | 1.73 Billion KRW | -26.29% |
| 2007 | 2.35 Billion KRW | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 119 Billion KRW | -1.65% |
| 2024 Q2 | 117 Billion KRW | -1.68% |
| 2023 Q1 | 185.79 Billion KRW | 0.19% |
| 2023 FY | 121 Billion KRW | -34.75% |
| 2023 Q3 | 196.82 Billion KRW | -0.92% |
| 2023 Q4 | 121 Billion KRW | -38.52% |
| 2023 Q2 | 198.66 Billion KRW | 6.92% |
| 2022 Q4 | 185.44 Billion KRW | 0.68% |
| 2022 Q3 | 184.2 Billion KRW | 0.31% |
| 2022 FY | 185.44 Billion KRW | 1.39% |
| 2022 Q1 | 183.26 Billion KRW | 0.2% |
| 2022 Q2 | 183.63 Billion KRW | 0.2% |
| 2021 Q3 | 182.72 Billion KRW | 58.64% |
| 2021 Q2 | 115.18 Billion KRW | 80.59% |
| 2021 FY | 182.9 Billion KRW | 401.87% |
| 2021 Q1 | 63.77 Billion KRW | 75.01% |
| 2021 Q4 | 182.9 Billion KRW | 0.1% |
| 2020 FY | 36.44 Billion KRW | 90.25% |
| 2020 Q1 | 26.81 Billion KRW | 39.98% |
| 2020 Q2 | 19.72 Billion KRW | -26.44% |
| 2020 Q3 | 27.81 Billion KRW | 41.0% |
| 2020 Q4 | 36.44 Billion KRW | 31.04% |
| 2019 Q2 | 35.89 Billion KRW | 0.88% |
| 2019 Q3 | 20.3 Billion KRW | -43.43% |
| 2019 FY | 19.15 Billion KRW | -45.69% |
| 2019 Q4 | 19.15 Billion KRW | -5.66% |
| 2019 Q1 | 35.57 Billion KRW | 0.88% |
| 2018 Q2 | 34.63 Billion KRW | 0.88% |
| 2018 Q1 | 34.33 Billion KRW | 0.88% |
| 2018 Q4 | 35.26 Billion KRW | 1.1% |
| 2018 FY | 35.26 Billion KRW | 3.61% |
| 2018 Q3 | 34.88 Billion KRW | 0.7% |
| 2017 Q3 | 33.73 Billion KRW | 0.0% |
| 2017 FY | 34.03 Billion KRW | 0.0% |
| 2017 Q4 | 34.03 Billion KRW | 0.9% |
| 2017 Q1 | - KRW | 0.0% |
| 2016 Q4 | - KRW | 0.0% |
| 2016 Q2 | - KRW | 0.0% |
| 2016 FY | - KRW | 0.0% |
| 2016 Q1 | - KRW | 0.0% |
| 2015 Q4 | - KRW | 0.0% |
| 2015 FY | - KRW | 0.0% |
| 2015 Q3 | - KRW | 0.0% |
| 2015 Q2 | - KRW | 0.0% |
| 2015 Q1 | - KRW | 0.0% |
| 2014 Q4 | - KRW | 0.0% |
| 2014 Q3 | - KRW | 0.0% |
| 2014 Q1 | - KRW | 0.0% |
| 2014 Q2 | - KRW | 0.0% |
| 2014 FY | - KRW | 0.0% |
| 2013 Q1 | - KRW | 0.0% |
| 2013 Q3 | - KRW | 0.0% |
| 2013 Q4 | - KRW | 0.0% |
| 2013 Q2 | - KRW | 0.0% |
| 2013 FY | - KRW | 0.0% |
| 2012 Q1 | - KRW | 0.0% |
| 2012 Q3 | - KRW | 0.0% |
| 2012 Q4 | - KRW | 0.0% |
| 2012 FY | - KRW | 0.0% |
| 2012 Q2 | - KRW | 0.0% |
| 2011 Q2 | 121.28 Million KRW | -59.1% |
| 2011 Q1 | 296.53 Million KRW | -27.49% |
| 2011 Q3 | 69.76 Million KRW | -42.48% |
| 2011 Q4 | - KRW | -100.0% |
| 2011 FY | - KRW | -100.0% |
| 2010 Q3 | 544.69 Million KRW | -27.25% |
| 2010 FY | 408.95 Million KRW | -63.15% |
| 2010 Q4 | 408.95 Million KRW | -24.92% |
| 2010 Q2 | 748.7 Million KRW | 0.0% |
| 2009 FY | 1.1 Billion KRW | -36.0% |
| 2008 FY | 1.73 Billion KRW | -26.29% |
| 2007 FY | 2.35 Billion KRW | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 13.64 Billion KRW | -787.094% |
| Dong-A Socio Holdings Co., Ltd. | 202.06 Billion KRW | 40.117% |
| Ildong Holdings Co., Ltd. | 29.87 Billion KRW | -304.999% |
| HANDOK Inc. | 123.78 Billion KRW | 2.246% |
| Kukje Pharma Co., Ltd. | 475.74 Million KRW | -25333.911% |
| Yuhan Corporation | 60.23 Billion KRW | -100.884% |
| Dong-A ST Co., Ltd. | 161.99 Billion KRW | 25.305% |
| SAMSUNG PHARM. Co., LTD. | 101.81 Million KRW | -118739.743% |
| Hanmi Pharm. Co., Ltd. | 82.02 Billion KRW | -47.51% |
| Hanall Biopharma Co.,Ltd | 590.3 Million KRW | -20397.733% |
| Ilyang Pharmaceutical Co.,Ltd | 6.05 Billion KRW | -1900.0% |
| Dong Sung Bio Pharm.Co.,Ltd. | 18.52 Billion KRW | -553.263% |
| MYUNGMOON Pharm co.,Ltd | 12.58 Billion KRW | -861.523% |
| Hana Pharm Co., Ltd. | 1.59 Billion KRW | -7467.959% |
| Yuyu Pharma, Inc. | 13.64 Billion KRW | -787.094% |
| Ilsung Pharmaceuticals Co., Ltd. | 119.67 Million KRW | -101004.293% |
| Aprogen pharmaceuticals,Inc. | 32 Billion KRW | -278.125% |
| JW Holdings Corporation | 20.65 Billion KRW | -485.748% |
| Ildong Pharmaceutical Co., Ltd. | 14.82 Billion KRW | -716.179% |
| Chong Kun Dang Pharmaceutical Corp. | 30 Billion KRW | -303.333% |
| JW Pharmaceutical Corporation | 30 Billion KRW | -303.333% |
| Shin Poong Pharm.Co.,Ltd. | 218.96 Million KRW | -55160.983% |
| Hyundai Pharmaceutical Co., Ltd. | 580.64 Million KRW | -20738.854% |
| Samil Pharmaceutical Co.,Ltd | 49.56 Billion KRW | -144.107% |
| Jeil Pharmaceutical Co.,Ltd | 4.45 Billion KRW | -2617.877% |
| Yuyu Pharma, Inc. | 13.64 Billion KRW | -787.094% |
| Kwang Dong Pharmaceutical Co., Ltd. | 19.02 Billion KRW | -535.916% |
| Daewoong pharmaceutical Co.,Ltd | 93.41 Billion KRW | -29.529% |
| JW Pharmaceutical Corporation | 30 Billion KRW | -303.333% |
| Yuhan Corporation | 60.23 Billion KRW | -100.884% |
| Jeil Pharma Holdings Inc | 10.5 Billion KRW | -1052.381% |
| Yungjin Pharm. Co., Ltd. | 40.37 Billion KRW | -199.67% |
| Suheung Co., Ltd. | 74 Billion KRW | -63.498% |
| JW Pharmaceutical Corporation | 30 Billion KRW | -303.333% |
| Samjin Pharmaceuticals Co., Ltd. | 4.16 Billion KRW | -2804.019% |
| Korea United Pharm Inc. | 10.96 Billion KRW | -1003.763% |
| CKD Bio Corp. | 69.43 Billion KRW | -74.273% |
| Daewon Pharmaceutical Co., Ltd. | 34.57 Billion KRW | -249.966% |
| Dongwha Pharm.Co.,Ltd | 16.12 Billion KRW | -650.263% |
| Whan In Pharm Co.,Ltd. | 307.05 Million KRW | -39306.464% |
| Shin Poong Pharm.Co.,Ltd. | 218.96 Million KRW | -55160.983% |
| Chong Kun Dang Holdings Corp. | 72.11 Billion KRW | -67.794% |
| Boryung Corporation | 151.7 Billion KRW | 20.242% |
| Bukwang Pharmaceutical Co., Ltd. | 78.52 Billion KRW | -54.091% |
| Ilyang Pharmaceutical Co.,Ltd | 6.05 Billion KRW | -1900.0% |
| JW Lifescience Corporation | 168 Million KRW | -71923.81% |